BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
370.33
-1.23 (-0.33%)
Oct 30, 2026, 4:00 PM EDT - Market closed
BeOne Medicines AG Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 42,107 | 33,619 | 19,667 | 18,862 | 22,843 | 27,843 | |
Market Cap Growth | 20.82% | 70.94% | 4.27% | -17.43% | -17.96% | 18.51% |
Enterprise Value | 39,059 | 31,487 | 18,005 | 16,441 | 18,473 | 24,626 |
Last Close Price | 370.33 | 303.81 | 184.71 | 180.36 | 219.94 | 270.93 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 66.29 | 117.17 | - | - | - | - |
Forward PE | 45.99 | 66.95 | 76.37 | 76.37 | 76.37 | 76.37 |
PS Ratio | 6.87 | 6.29 | 5.16 | 7.67 | 16.13 | 23.67 |
PB Ratio | 8.09 | 7.71 | 5.90 | 5.33 | 5.21 | 4.54 |
P/TBV Ratio | 8.24 | 7.82 | 5.99 | 5.42 | 5.26 | 4.58 |
P/FCF Ratio | 31.66 | 35.70 | - | - | - | - |
P/OCF Ratio | 28.37 | 29.82 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 6.37 | 5.89 | 4.72 | 6.69 | 13.05 | 20.94 |
EV/EBITDA Ratio | 36.45 | 54.40 | - | - | - | - |
EV/EBIT Ratio | 42.31 | 70.42 | - | - | - | - |
EV/FCF Ratio | 29.36 | 33.44 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.40 | 0.46 | 0.32 | 0.26 | 0.14 | 0.11 |
Debt / EBITDA Ratio | 1.86 | 3.28 | - | - | - | - |
Debt / FCF Ratio | 1.54 | 2.12 | - | - | - | - |
Net Debt / Equity Ratio | -0.59 | -0.58 | -0.46 | -0.63 | -0.90 | -0.97 |
Net Debt / EBITDA Ratio | -2.84 | -4.40 | 3.86 | 2.00 | 2.28 | 4.25 |
Net Debt / FCF Ratio | -2.29 | -2.70 | 2.44 | 1.30 | 2.16 | 3.80 |
Asset Turnover | 0.79 | 0.76 | 0.65 | 0.40 | 0.19 | 0.17 |
Inventory Turnover | 1.10 | 1.21 | 1.30 | 1.09 | 1.09 | 0.99 |
Quick Ratio | 2.91 | 2.97 | 1.51 | 1.97 | 3.22 | 4.45 |
Current Ratio | 3.41 | 3.41 | 1.80 | 2.32 | 3.55 | 4.76 |
Return on Equity (ROE) | 14.66% | 7.46% | -18.77% | -22.26% | -38.11% | -29.15% |
Return on Assets (ROA) | 7.46% | 3.96% | -6.06% | -12.39% | -15.00% | -12.72% |
Return on Invested Capital (ROIC) | 33.62% | 17.11% | -36.89% | -138.75% | -401.98% | - |
Return on Capital Employed (ROCE) | 13.10% | 7.00% | -15.30% | -30.20% | -36.40% | -20.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.51% | 0.85% | -3.28% | -4.67% | -8.77% | -5.24% |
FCF Yield | 3.16% | 2.80% | -3.22% | -9.12% | -7.98% | -5.61% |
Buyback Yield / Dilution | -8.01% | -7.75% | -0.86% | -1.22% | -11.15% | -11.16% |